Pharming shares rise 5% as 2025 preliminary revenue exceeds guidance
08/01/2026 09:02
** Shares in Pharming Group PHAR.AS jump 5% after the Dutch biotech company reported preliminary 2025 revenue of $376 million (322 million euros), exceeding the high end of its $365-375 million guidance ** Revenue growth was driven by growth for its Ruconest drug and rising demand of Joenja, Pharming says ** Kempen analyst Sebastian Hernandez points to the company's financial discipline, with operating expenses remaining within the guided range of $304-308 million, as a key contributing factor to the positive sentiment ** The results confirm expectations of a stronger Q4 and earlier management guidance, Hernandez adds ** If the gains hold, Pharming shares are on track for their best day since November 6, 2025 (1 euro = $1.1672) (Reporting by Jerome Terroy) ((Jerome.Terroy@thomsonreuters.com;))